Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2020 | editorial

Therapies in flux: highlights of the 2019 San Antonio Breast Cancer Symposium (SABCS)

verfasst von: Simon Peter Gampenrieder

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Auszug

The San Antonio Breast Cancer Symposium (SABCS) in Texas, USA, is an annual highlight for breast cancer researchers from all over the world. Nearly every year, practice-changing clinical trials or meta-analyses are presented at this focused international meeting. In addition to these large studies, the meeting distinguishes itself by excellent scientific and educational sessions as well as a large poster session displaying the many-sided facets of breast cancer over five consecutive days. …
Vorheriger Artikel Rectal cancer: latest developments and innovative new treatment concepts
Nächster Artikel Managing an oncology clinic during the COVID-19 pandemic—how we did it in Sarajevo?
Literatur
1.
Murthy R, et al. Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB). Cancer Res. 2020;80(4 Supplement):GS1–01.
2.
Krop IE, et al. Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T‑DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01). Cancer Res. 2020;80(4 Supplement):GS1–03.
3.
Schmid P, et al. Abstract GS3-03: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early triple-negative breast cancer: pathologic complete response in key subgroups and by treatment exposure, residual cancer burden, and breast-conserving surgery. Cancer Res. 2020;80(4 Supplement):GS3–03.
4.
Sestak I, et al. Abstract GS4-03: Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study. Cancer Res. 2020;80(4 Supplement):GS4–03.
5.
Li J, et al. Abstract GS1-08: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): An open-label, randomised, multicentre, phase 3 trial. Cancer Res. 2020;80(4 Supplement):GS1–08.
6.
van Mackelenbergh M, et al. Abstract GS1-07: Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Cancer Res. 2020;80(4 Supplement):GS1–07.
7.
Cuzick J, et al. Abstract GS4-04: Ten year results of the international breast cancer intervention study II. Cancer Res. 2020;80(4 Supplement):GS4–04.
8.
De Censi A. Abstract ES3-3: Low dose tamoxifen and other approaches to improve chemoprevention uptake. Cancer Res. 2020;80(4 Supplement):ES3–3.
9.
Heil J, et al. Abstract GS5-03: Diagnosing residual disease and pathologic complete response after neoadjuvant chemotherapy in breast cancer patients by image-guided vacuum-assisted breast biopsy: Results of a prospective multicenter trial. Cancer Res. 2020;80(4 Supplement):GS5–03.
10.
Tasoulis MK, et al. Abstract GS5-04: Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: A multi-institutional pooled analysis. Cancer Res. 2020;80(4 Supplement):GS5–04.
11.
Peeters M‑JTFDV, et al. Abstract GS5-06: Towards omitting breast surgery in patients with a pathologic complete response after neoadjuvant systemic treatment: interim analysis of the MICRA trial (Minimally Invasive Complete Response Assessment). Cancer Res. 2020;80(4 Supplement):GS5–06.
12.
Basik M, et al. Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery. Cancer Res. 2020;80(4 Supplement):GS5–05.
Metadaten
Titel
Therapies in flux: highlights of the 2019 San Antonio Breast Cancer Symposium (SABCS)
verfasst von
Simon Peter Gampenrieder
Publikationsdatum
01.09.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00635-8

Weitere Artikel der Ausgabe 3/2020

The future of combination therapies in advanced melanoma

  • Open Access
  • short review

Adjuvant and neoadjuvant treatment of melanoma

  • Open Access
  • short review

Myeloid diseases—Chronic Myeloid Leukemia (CML)—report from ASH 2019 on new developments

  • short review

Treatment options in early triple-negative breast cancer

  • Open Access
  • short review

ASH highlights 2019: “aggressive B-cell lymphoma”

  • Open Access
  • short review

Patient-reported outcomes and psycho-oncological screening in hematology: a practical example of routine electronic monitoring

  • Open Access
  • review